Leads Biolabs, opamtistomig, LBL-024, Fast Track Designation, FDA, biliary tract cancer, BTC, PD-L1, 4-1BB, bispecific antibody, cancer immunotherapy, Phase II clinical trial,

NANJING, China — October 12, 2026 Nanjing Leads Biolabs Co., Ltd. announced that the U.S. Food and Drug Administration...